Global Artificial Intelligence in Bioinformatics Market Overview
As per MRFR analysis, the Artificial Intelligence in Bioinformatics Market Size was estimated at 6.71 (USD Billion) in 2022.
The Artificial Intelligence in Bioinformatics Market Industry is expected to grow from 7.67 (USD Billion) in 2023 and USD 8.77 billion in 2024 to 25.5 (USD Billion) by 2032. The Artificial Intelligence in Bioinformatics Market CAGR (growth rate) is expected to be around 14.27% during the forecast period (2023 - 2032).
Key Artificial Intelligence in Bioinformatics Market Trends Highlighted
The Artificial Intelligence (AI) in the Bioinformatics market is poised for significant growth, driven by the rising adoption of AI technologies in healthcare and the increasing demand for personalized medicine. The market is expected to expand at a CAGR of 14.27%, reaching a market size of USD 25.5 billion by 2032.
Some of the key market drivers in the AI in bioinformatics market include a higher rate of occurrence of chronic diseases, the increased necessity for early diagnosis and treatment, the fast development of AI algorithms, and computational power. Equally important, government policies aimed at encouraging personalized medicine and health IT are stimulating market growth.
Opportunities for expansion are present in incorporating AI into different bioinformatics uses, including drug discovery, disease diagnosis, and customized therapy plans. In addition, AI's utilization in cloud computing and edge computing is giving birth to new prospects for its growth in the market. The most recent trends encompass AI-fueled bioinformatics platforms, machine learning employed in genetic variant interpretation, and deep learning applied to image-based diagnostics. With these advancements harnessed, the Artificial Intelligence Market will continue revolutionizing healthcare, leading to better personalized treatments and opening up new possibilities.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Bioinformatics Market Drivers
-
Advancements in Technology to Increase Market Growth
Bioinformatics has grown so fast that AI technology is staggering forward, thus allowing researchers to rapidly and efficiently analyze huge amounts of biological data. In the next decade, technological innovations in AI are expected to significantly propel the growth of artificial intelligence in the bioinformatics market industry on a global scale. Some major technical advances include improved algorithms and machine learning methods. AI algorithms have become more intelligent, making them able to identify patterns more accurately and, hence, make predictions. This has led to the development of better AI-based tools for bioinformatics research.
There is much more biological data, such as genomic and proteomic information, leading to greater learning possibilities for AI algorithms. Therefore, building AI models will be highly accurate and reliable. Introduction of cloud-based platforms: Cloud-based platforms democratize access to artificial intelligence technologies for researchers who cannot afford their own infrastructure.
As a result, this will further boost the adoption rates of these technologies in bioinformatics. Continuous improvements in artificial intelligence technology are expected to define the trend of global growth of AI in the bioinformatics market industry over the next several years.
-
Growing Demand for Personalized Medicine
The field of personalized medicine, which is growing rapidly, aims at providing medical care that meets the unique needs of each patient. Personalized medicine, thanks to AI, has revolutionized how doctors can go through massive patient data to identify common features and predict what might happen to a given individual. In such an example, this data could be used to formulate better treatment plans that are more effective and individualized.
-
Increasing Adoption of AI in Drug Discovery and Development
Further, the Application of artificial intelligence in drug discovery and development is advancing at pace. Consequently, AI-based tools may be used to scan millions of substances for promising drugs, detect new drug targets, and foresee the effectiveness and safety of newly designed medications. This will speed up the process of developing new drugs and make it more efficient.
Artificial Intelligence in Bioinformatics Market Segment Insights
Artificial Intelligence in Bioinformatics Application Insights
The Artificial Intelligence in Bioinformatics Market segmentation by Application is expected to reach a value of USD 10.2 billion by 2027, exhibiting a CAGR of 12.5% during the forecast period (2023-2027). Drug Discovery is a major application of AI in bioinformatics, with a market size of USD 2.5 billion in 2023 and an expected growth of USD 5.2 billion by 2027. AI can be used to analyze large datasets of biological data, including genomics, proteomics, and metabolomics data, to identify potential drug targets and develop new drugs more quickly and efficiently.
Biomarker Identification is another important application of AI in bioinformatics, with a market size of USD 1.8 billion in 2023 and an expected growth of USD 3.6 billion by 2027. AI can be used to identify biomarkers that can be used to diagnose diseases earlier and more accurately, as well as to develop personalized treatments. Genomics Analysis is a rapidly growing application of AI in bioinformatics, with a market size of USD 1.5 billion in 2023 and an expected growth of USD 2.9 billion by 2027. AI can be used to analyze large datasets of genomic data to identify genetic variants that are associated with diseases and to develop new treatments for genetic diseases.
Proteomics Analysis is another important application of AI in bioinformatics, with a market size of USD 1.2 billion in 2023 and an expected growth of USD 2.3 billion by 2027. AI can be used to analyze large datasets of proteomics data to identify proteins that are associated with diseases and to develop new treatments for diseases that are caused by protein dysfunction. Metabolomics Analysis is a rapidly growing application of AI in bioinformatics, with a market size of USD 1.0 billion in 2023 and an expected growth of USD 2.0 billion by 2027.
AI can be used to analyze large datasets of metabolomics data to identify metabolites that are associated with diseases and to develop new treatments for diseases that are caused by metabolic disorders.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Bioinformatics Deployment Mode Insights
On the basis of deployment mode, Artificial Intelligence in Bioinformatics Market can be categorized into cloud-based and on-premise. The bioinformatics field is witnessing widespread acceptance of cloud computing, a development that may have the cloud-based category controlling most of the market by 2023. All this has been possible thanks to cloud-based deployments, which are cost-effective, flexible, and scalable, among other benefits. Moreover, as they are web-based AI-driven bioinformatics tools and applications for planet-wide use, they do not call for any on-site infrastructure or maintenance.
However, it is anticipated that there will be a sluggish growth rate in the on-premise segment during the forecast period. On-premise deployments offer greater control and data security, particularly when supporting sensitive bioinformatics software.
Nevertheless, some firms might find it costly to set up and maintain infrastructure. In general, organizations will focus on deploying this technology through cloud-based methods since they want to enjoy its advantages, such as the low costs associated with procuring hardware and software, among others, in their bioinformatics requirements.
Artificial Intelligence in Bioinformatics End User Insights
One of the key benefits of Artificial Intelligence in Bioinformatics Market is that it has been adopted by top-end users such as pharmaceutical and biotechnology companies, research institutes, CDMOs & CROs, etc., as a major tool. The Application of AI in drug discovery or development has made pharmaceutical and biotechnology companies dominate the market extensively. The global artificial intelligence bioinformatics market revenue was valued at USD 7.67 billion in 2023. This gives rise to an increased adoption of AI as a means of analysis and interpretation to drive the market.
AI is necessary for healthcare providers since it improves patient care in personalized medicine and early disease detection. To expand the market, governments invest in AI as part of public health initiatives. This industry's growth and innovation are driven by its adaptability to various end-users within bioinformatics, such as AI, based on different types of data sets across all types of medical information system users.
Artificial Intelligence in Bioinformatics Regional Insights
North America is anticipated to be the market leader in the region, and it will take up a sizeable amount by 2023. This region’s domination is due to having major technology players, advanced healthcare infrastructure developments, and AI-based surrogates in the biotechnology industry. Europe will come second because of increased spending on AI research and development as well as other government incentives that also support their use in healthcare and life sciences industries. The APAC region will experience outstanding growth during the forecast period compared to other regions, mainly due to an increase in personalized medicine demand, high healthcare costs, and government support for AI adoption into medical practice.
Nevertheless, South America and MEA are projected to have lower contributions towards the whole market, but they are forecasted to grow at considerable rates owing to advances made in AI-based drug discovery and precision medicines.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Bioinformatics Market Key Players and Competitive Insights:
Artificial intelligence in Bioinformatics market has been dominated by key players who are always striving to be ahead of their competitors through the creation of new products and solutions. The leading players in the Artificial intelligence bioinformatics market heavily invest in R&D so as to stay ahead of the current and adapt to the changing needs of customers. Strategic collaborations, partnerships, and acquisitions are among the characteristics that define the development landscape of Artificial Intelligence in Bioinformatics Market as firms seek to expand their portfolios, reach into new technologies, and explore new markets.
IBM is one of the major players in the Artificial Intelligence in Bioinformatics Market. Watson for Genomics represents a comprehensive portfolio of AI-enabled bioinformatics tools developed by IBM. It helps researchers process enormous genomics data sets. IBM has a strong presence across healthcare and life sciences industries, thus leveraging its domain expertise to drive AI adoption in bioinformatics. Another key player within this industry is Illumina, which is an AI-based high-throughput sequencing provider with various supportive genomic research tools they developed. The main objective behind developing these AI-based approaches at Illumina includes identifying genetic variations, analyzing gene expression data, and coming up with personalized medications.
Thermo Fisher Scientific, QIAGEN, and Agilent Technologies are also other significant participants of Artificial Intelligence in Bioinformatics Market besides IBM and Illumina. These firms provide a wide array of AI-driven bioinformatic solutions that include analytics tools for drug discovery or precision medicine. There is stiff competition among these companies, so they constantly innovate to avoid being outdone.
Key Companies in the Artificial Intelligence in Bioinformatics Market Include:
- Roche
- Illumina
- Agilent Technologies
- BioRad Laboratories
- QIAGEN
- Bionano Genomics
- MGI Tech
- NanoString Technologies
- Oxford Nanopore Technologies
- 10x Genomics
- Thermo Fisher Scientific
- PacBio
Artificial Intelligence in Bioinformatics Market Industry Developments
To sum up, the adoption of AI in life sciences and healthcare will drive AI bioinformatics market growth significantly in the next few years. Increased database availability is among the major factors that are increasing market expansion. Moreover, the rise in cases of chronic ailments and individualized medication are also some of the drivers of this industry.
Of note, there have been recent changes that have led to the Introduction of new bioinformatics platforms based on AI. For instance, in 2023, IBM and Recursion Pharmaceuticals joined forces to use artificial intelligence (AI) in searching for drugs that can cure various rare diseases.
Major companies such as Microsoft, Google, Amazon, Oracle, and IBM are among the notable players here. These firms have made considerable investments towards developing AI-driven innovative bioinformatics solutions through research and development activities.
Artificial Intelligence in Bioinformatics Market Segmentation
Artificial Intelligence in Bioinformatics Application Outlook
- Drug Discovery
- Biomarker Identification
- Genomics Analysis
- Proteomics Analysis
- Metabolomics Analysis
Artificial Intelligence in Bioinformatics Deployment Mode Outlook
Artificial Intelligence in Bioinformatics Data Offering Outlook
Artificial Intelligence in Bioinformatics End User Outlook
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CDMO & CROs
- Others
Artificial Intelligence in Bioinformatics Regional Outlook
- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2022
|
6.71(USD Billion)
|
|
Market Size 2023
|
7.67(USD Billion)
|
|
Market Size 2032
|
25.5(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
14.27% (2023 - 2032)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2023 - 2032
|
|
Historical Data
|
2019 - 2023
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Roche, Illumina, Agilent Technologies, BioRad Laboratories, QIAGEN, Bionano Genomics, MGI Tech, NanoString Technologies, Oxford Nanopore Technologies, 10x Genomics, Thermo Fisher Scientific, PacBio
|
|
Segments Covered
|
Application, Deployment Mode, Data Source, Function, End User, Regional
|
|
Key Market Opportunities
|
Drug Discovery Precision Medicine Genomics Bioinformatics Healthcare
|
|
Key Market Dynamics
|
Growing demand for personalized medicine, Advancements in computing technologies Increasing adoption of cloud-based solutions, Growing focus on precision medicine and Government initiatives supporting AI research
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Frequently Asked Questions (FAQ) :
This is projected to reach approximately USD 25.5 bn by 2032, growing at a CAGR of about 14.27% from 2023-2032.
These include diverse areas such as drug discovery, disease diagnosis, personalized medicine, and bioinformatics research.
The largest market share should be expected for North America, followed by Europe and Asia-Pacific, but during the forecast period, it is also anticipated that the latter will grow with a high CAGR.
Major rivals include IBM, Google, Microsoft, Amazon and Oracle.
To mention a few problems here, we may note the absence of well-trained AI experts, the high utilization costs associated with AI, and the ethical issues relating to the medical use of AI.
This includes increased adoption of cloud-based AI platforms, the Introduction of new AI algorithms, and the rise in AI use for precision medicine.
It is worth mentioning such issues as increasing demand for personalized medicine, fast growth rates on drug discovery with respect to usage of AI technologies, and the emergence of novel tools containing elements of AI into bioinformatic studies as well – all this gives other answers concerning prospective development rates for this market segment effectively guided towards finding hope for potential success among newbies entering or those already operating here themselves.
Global market size will reach 25.5 million USD by 2032 from an estimated 16 billion USD at a CAGR of 14% up until the end of year 2023.
The surging demand for personalized drugs is resulting from the widespread adoption of various healthcare systems alongside an increasing number of health problems requiring individual approaches. The growing application sphere includes new AI-based bioinformatics tools and the increasing use of AI in healthcare.
Lack of trained, skilled AI professionals, the cost of implementing AI is high, and there are ethical issues related to using it in the medical field.
